Frexalimab

Frexalimab is an experimental drug that is currently being studied for its potential use in the treatment of various autoimmune diseases. It is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R), a protein that plays a key role in the immune response.

Mechanism of action[edit | edit source]

Frexalimab works by binding to the IL-6R, thereby blocking the interaction between IL-6 and its receptor. This prevents the activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, which is involved in the production of inflammatory cytokines.

Clinical trials[edit | edit source]

Several clinical trials have been conducted to evaluate the safety and efficacy of frexalimab in patients with autoimmune diseases. These trials have shown promising results, with patients experiencing a reduction in disease activity and an improvement in quality of life.

Potential applications[edit | edit source]

Frexalimab is being investigated for its potential use in the treatment of a variety of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. It may also have potential applications in the treatment of other inflammatory conditions, such as psoriasis and asthma.

See also[edit | edit source]

Frexalimab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.